<DOC>
	<DOCNO>NCT00007995</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : This phase II trial study well chemotherapy peripheral stem cell transplant work treat patient multiple myeloma primary systemic amyloidosis .</brief_summary>
	<brief_title>Chemotherapy Plus Peripheral Stem Cell Transplant Treating Patients Who Have Multiple Myeloma Primary Systemic Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient multiple myeloma primary systemic amyloidosis treat high-dose chemotherapy autologous hematopoietic stem cell support . - Determine toxicity regimen patient . - Determine disease-free survival overall survival patient multiple myeloma treated regimen . OUTLINE : Patients stratify accord disease response prior treatment ( responsive v refractory relapse ) diagnosis ( multiple myeloma v primary systemic amyloidosis ) . Following course induction chemotherapy , patient receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily completion peripheral blood stem cell ( PBSC ) harvesting . Patient mobilize sufficient cell undergo bone marrow harvest . Patients receive melphalan IV 30 minute day -2 -1 . Half store PBSCs and/or bone marrow reinfused day 0 . Patients receive sargramostim ( GM-CSF ) daily begin day 0 continue blood count recover . Patients primary systemic amyloidosis respond unable tolerate treatment proceed second course therapy . Within 4-6 week receive melphalan , patient receive oral busulfan day -8 -5 follow cyclophosphamide IV continuously day -4 -3 . The remain half PBSCs and/or bone marrow reinfused day 0 . Patients receive GM-CSF daily begin day 0 continue blood count recover . Within 4-12 week receive second course high-dose chemotherapy , multiple myeloma patient receive maintenance therapy consist interferon alfa SC 3 day week , blood count recover . Patients follow every 3 month 1 year annually 5 year . PROJECTED ACCRUAL : Approximately 60-75 patient ( 25 responsive disease stratum , 25 refractory relapse disease stratum , 10-25 primary systemic amyloidosis stratum ) accrue study within 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma OR Primary systemic amyloidosis result significant organ dysfunction decrease quality life Complete partial response standard chemotherapy Primary refractory relapse multiple myeloma firstline treatment standard chemotherapy Ineligible high priority national institutional clinical study PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2 time normal Renal : Creatinine le 2.5 mg/dL stable hemodialysis Cardiovascular : LVEF least 45 % Pulmonary : DLCO least 60 % predict OR Approval pulmonologist Other : HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Concurrent participation gene therapy trial allow Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : No concurrent steroid antiemetic chemotherapy No concurrent anticancer hormonal therapy Radiotherapy : Not specify Surgery : Not specify Other : No concurrent barbiturates acetaminophen chemotherapy Concurrent participation supportive care trial allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>